Avishek Bhuniya
Overview
Explore the profile of Avishek Bhuniya including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
220
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Das J, Bera S, Ganguly N, Guha I, Halder T, Bhuniya A, et al.
Front Immunol
. 2024 Dec;
15:1470330.
PMID: 39624093
[This corrects the article DOI: 10.3389/fimmu.2024.1325161.].
2.
Tcyganov E, Kwak T, Yang X, Poli A, Hart C, Bhuniya A, et al.
bioRxiv
. 2024 May;
PMID: 38798466
Statement Of Significance: Currently, targeting immunosuppressive myeloid cells in ovarian cancer microenvironment is the first priority need to enable successful immunotherapy, but no effective solutions are clinically available. We show...
3.
Ganguly N, Das T, Bhuniya A, Guha I, Chakravarti M, Dhar S, et al.
Cell Commun Signal
. 2024 Apr;
22(1):237.
PMID: 38649988
Background: A water-soluble ingredient of mature leaves of the tropical mahogany 'Neem' (Azadirachta indica), was identified as glycoprotein, thus being named as 'Neem Leaf Glycoprotein' (NLGP). This non-toxic leaf-component regressed...
4.
Das J, Bera S, Ganguly N, Guha I, Halder T, Bhuniya A, et al.
Front Immunol
. 2024 Apr;
15:1325161.
PMID: 38585261
Introduction: Murine tumor growth restriction by neem leaf glycoprotein (NLGP) was established in various transplanted models of murine sarcoma, melanoma and carcinoma. However, the role of NLGP in the sequential...
5.
Dhar S, Chakravarti M, Ganguly N, Saha A, Dasgupta S, Bera S, et al.
Front Immunol
. 2024 Feb;
14:1303959.
PMID: 38304256
Introduction: Non-Hodgkin Lymphoma (NHL) is a heterogeneous lymphoproliferative malignancy with B cell origin. Combinatorial treatment of rituximab, cyclophsphamide, hydroxydaunorubicin, oncovin, prednisone (R-CHOP) is the standard treatment regimen for NHL, yielding...
6.
Guha A, Goswami K, Sultana J, Ganguly N, Choudhury P, Chakravarti M, et al.
Front Immunol
. 2023 Dec;
14:1245421.
PMID: 38090567
Breast cancer (BC) is globally one of the leading killers among women. Within a breast tumor, a minor population of transformed cells accountable for drug resistance, survival, and metastasis is...
7.
Chakravarti M, Dhar S, Bera S, Sinha A, Roy K, Sarkar A, et al.
Cancer Res
. 2023 Mar;
83(11):1815-1833.
PMID: 36971604
Cross-talk with TTEX CD8+ T cells mediated by the VEGFR2 axis induces aggressive properties in cancer stem cells to promote tumor progression.
8.
Bhuniya A, Pattarayan D, Yang D
Mol Carcinog
. 2022 Sep;
61(12):1073-1081.
PMID: 36161729
Lentivirus-based transduction systems are widely used in biological science and cancer biology, including cancer immunotherapy. However, in in vivo transplanted tumor model, the immunogenicity of these transduced cells was not...
9.
Bhuniya A, Sarkar A, Guha A, Choudhury P, Bera S, Sultana J, et al.
Cytokine
. 2022 Aug;
158:155998.
PMID: 35981492
Extent of metastasis influences activation of platelets in tumor-microenvironment. Activated platelets potentiate mesenchymal-stem-cells (MSCs) to migrate in secondary metastatic sites without participation in process of invasion. Presence of higher percentage...
10.
Patidar A, Selvaraj S, Chakravarti M, Guha I, Bhuniya A, Bera S, et al.
Cytokine
. 2022 Apr;
154:155871.
PMID: 35436657
Elicitation of the tumor-eliminating immune response is a major challenge, as macrophages- constituting a major component of solid tumor mass- play important roles in development, maintenance and tumor regression. The...